Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

67.0K
Overview
67.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thymic alveolar type 2 epithelial mimetic cells revealed by RUNX1 deficiency.

Nature immunology·2026
Same author

DROP-CARs: Engineering Reversible, Drug-Controlled CAR T-cell Activity with a Clinically Approved Small Molecule.

Cancer research·2026
Same author

Spike-in probe-enhanced single-cell RNA-seq reveals post-infusion transcriptomic remodeling of "prime-and-kill" synNotch-CAR-T cells.

bioRxiv : the preprint server for biology·2026
Same author

Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy.

Cancer research·2025
Same author

TIGR-Tas: A family of modular RNA-guided DNA-targeting systems in prokaryotes and their viruses.

Science (New York, N.Y.)·2025
Same author

Programming tissue-sensing T cells that deliver therapies to the brain.

Science (New York, N.Y.)·2024

Related Experiment Video

Updated: Jun 5, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

125

Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs.

Nishith R Reddy1,2, Hasna Maachi3, Yini Xiao1,2,3

  • 1UCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.

Science (New York, N.Y.)
|December 5, 2024
PubMed
Summary

Researchers engineered T cells to precisely suppress immune responses locally. These synthetic suppressor T cells offer targeted immune regulation, protecting tissues from attack without causing systemic effects, potentially treating various immune-related conditions.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.8K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

8.7K

Related Experiment Videos

Last Updated: Jun 5, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

125
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.8K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

8.7K

Area of Science:

  • Immunology
  • Synthetic Biology
  • Cell Therapy

Background:

  • Immune homeostasis relies on balancing inflammatory and suppressive activities.
  • Current immune suppression strategies can lack specificity, leading to systemic side effects.

Purpose of the Study:

  • To engineer CD4+ T cells capable of antigen-triggered local immune suppression.
  • To develop a customizable platform for precise immune regulation in specific tissues.

Main Methods:

  • Conventional CD4+ T cells were engineered with synthetic Notch (synNotch) receptors.
  • Antigen-triggered production of anti-inflammatory factors (IL-10, TGF-β1, PD-L1) and cytokine sinks (CD25) was screened.
  • The efficacy of engineered cells was tested in models of tissue protection.

Main Results:

  • A combination of anti-inflammatory factors and cytokine sinks demonstrated potent suppression of cytotoxic T cell attack.
  • Engineered cells provided localized immune protection without systemic immunosuppression.
  • Synthetic suppressor T cells successfully protected transplanted beta cell organoids and tissues from CAR T cell cross-reaction.

Conclusions:

  • Synthetic suppressor T cells represent a novel, customizable platform for targeted immune modulation.
  • This approach offers potential therapeutic applications for autoimmune diseases, organ transplant rejection, and CAR T cell toxicities.
  • Spatial precision in immune suppression can be achieved, minimizing off-target effects.